% Susceptible
Click Here for Printable view| Ox | ||||||||||||||||||||||||||
75 |
+ |
97 |
+ |
+ |
+ |
+ |
86 |
95 |
+/- |
+ |
+/- |
98 |
+ |
- |
- |
- |
78 |
+ |
88 |
72 |
+ |
86 |
90 |
100 |
& |
|
2 |
- |
100 |
100 |
- |
+ |
100 |
+ |
100 |
+/- |
+ |
83 |
85 |
97 |
+ |
+ |
- |
98 |
+ |
+ |
65 |
+ |
95 |
83 |
100 |
99& |
|
0 |
0 |
0 |
0 |
- |
- |
0 |
- |
0 |
- |
- |
21 |
22 |
80 |
- |
- |
- |
97 |
- |
- |
5 |
- |
92 |
64 |
100 |
99& |
|
2 |
+-* |
43 |
43 |
+/- |
+-* |
+/- |
+/- |
43 |
+/- |
+/- |
53 |
50 |
63 |
89 |
+/- |
- |
59 |
+-* |
+-* |
35 |
+-* |
83 |
63 |
100 |
99& |
|
100 |
100 |
+ |
+ |
+ |
+ |
100 |
+ |
100 |
+ |
+ |
+/- |
98 |
+ |
- |
- |
- |
- |
+ |
+ |
50 |
+/- |
- |
62 |
+ |
& |
|
89 |
90 |
+ |
+- |
+ |
+ |
96 |
+ |
96 |
+/- |
+ |
+-* |
96 |
+ |
-* |
-* |
-* |
72 |
+ |
+ |
60 |
-* |
+ |
89 |
99 |
& |
|
100 |
100 |
+ |
- |
+ |
+ |
- |
- |
- |
- |
- |
61 |
67 |
+ |
71S |
S |
- |
- |
+ |
+/- |
- |
- |
20 |
- |
100 |
99& |
|
35 |
37 |
- |
+/- |
+/- |
- |
- |
- |
- |
- |
20 |
27 |
+/- |
63S |
- |
- |
- |
+/- |
- |
- |
- |
63 |
- |
53 |
58& |
||
- |
+/- |
+ |
- |
+/- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+/- |
+ |
+ |
+/- |
+ |
+ |
- |
- |
& |
||
- |
61 |
64 |
- |
63 |
98 |
91 |
95 |
98 |
98 |
98 |
85 |
86 |
+ |
93 |
93 |
99 |
79 |
100 |
+ |
- |
- |
79 |
- |
- |
96& |
|
- |
4 |
7 |
- |
74 |
87 |
1 |
5 |
79 |
85 |
+ |
98 |
98 |
+ |
98 |
98 |
82 |
86 |
99 |
+ |
- |
- |
- |
- |
- |
28& |
|
- |
1 |
91 |
- |
78 |
99 |
98 |
95 |
99 |
99 |
99 |
98 |
99 |
+ |
99 |
99 |
99 |
91 |
100 |
+ |
- |
- |
88 |
- |
- |
49& |
|
- |
60 |
90 |
- |
78 |
100 |
83 |
95 |
97 |
97 |
98 |
62 |
65 |
+ |
95 |
95 |
98 |
60 |
98 |
+ |
-* |
-* |
2 |
-* |
-* |
0 |
|
- |
- |
- |
- |
97 |
98 |
- |
- |
32 |
95 |
91 |
82 |
81 |
+ |
82 |
97 |
80 |
- |
93 |
+ |
- |
- |
- |
- |
- |
- |
|
- |
4 |
3 |
- |
83 |
93 |
0 |
0 |
97 |
92 |
96 |
93 |
95 |
+ |
99 |
93 |
94 |
94 |
99 |
+ |
- |
- |
16 |
- |
- |
0 |
|
- |
7 |
11 |
- |
78 |
95 |
0 |
15 |
84 |
82 |
+ |
93 |
96 |
+ |
95 |
93 |
85 |
82 |
100 |
+ |
- |
80 |
- |
- |
92& |
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin
(&) nitrofurantoin only useful for lower tract urinary tract infections
Pen(penicillin), Amp(ampicillin), Uns(Unasyn/Augmentin), Ox(Oxacillin/Nafcillin), Pip(piperacillin), P/T(piperacillin/tazobactam), Cfz(cefazolin), Cfr(cefuroxime), Cft(ceftriaxone), Ctz(Ceftazidime), Cfp(Cefepime), Cip(ciprofloxacin), Lev(levofloxacin), Mox(moxifloxacin), Gen(gentamicin), Tob(tobramycin), Azt(aztreonam), T/S(trimethoprim/sulfamethoxazole), Imp(imipenem), Mer(meropenem), Ery(erythromycin), Azi(azithromycin), Dox(doxycycline), Cln(Clindamycin), Van(Vancomycin), Ntf(nitrofurantoin)
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin
(&) nitrofurantoin only useful for lower tract urinary tract infections
Pen(penicillin), Amp(ampicillin), Uns(Unasyn/Augmentin), Ox(Oxacillin/Nafcillin), Pip(piperacillin), P/T(piperacillin/tazobactam), Cfz(cefazolin), Cfr(cefuroxime), Cft(ceftriaxone), Ctz(Ceftazidime), Cfp(Cefepime), Cip(ciprofloxacin), Lev(levofloxacin), Mox(moxifloxacin), Gen(gentamicin), Tob(tobramycin), Azt(aztreonam), T/S(trimethoprim/sulfamethoxazole), Imp(imipenem), Mer(meropenem), Ery(erythromycin), Azi(azithromycin), Dox(doxycycline), Cln(Clindamycin), Van(Vancomycin), Ntf(nitrofurantoin)
